20
SPINE
SURGEONS
Johnson & Johnson,
US Defense Dept.
Reach $260M Deal on
Orthopedic Devices — 4
Takeaways
By Adam Schrag
J
ohnson & Johnson was awarded a contract to
supply the U.S. Defense Department with or-
thopedic devices, according to Mass Device.
Here are four things to know:
1. The one-year contract includes four additional
one-year options.
2. The agreement's total maximum value is
roughly $260.5 million.
3. Johnson & Johnson will supply the Army,
Navy, Air Force, Marine Corps and federal civil-
ian agencies with orthopedic products.
4. The agreement took place on Sat., April 27,
2017 and will expire on April 27, 2022. n
1,200+ ATTENDEES
FROM ACROSS THE NATION
REGISTER BY SEPTEMBER 1, 2017 AND SAVE!
KEYNOTES BY
24
TH
ANNUAL
MEETING:
THE BUSINESS &
OPERATIONS OF ASCS
OCTOBER 26-28, 2017
SWISSOTEL | CHICAGO, ILLINOIS
190 SPEAKERS, INCLUDING
137+ SPEAKERS DIRECTLY FROM
SURGERY CENTERS
Register here at www.beckersasc.com/annual-
ambulatory-surgery-centers-conference/
Call 800-417-2035 or email Jessica Cole at
jcole@beckershealthcare.com or
Scott Becker at sbecker@beckershealthcare.com
The Best Business-Focused, Strategic
Discussions in the ASC Industry with a Special
AEU Credit Track
BECKER'S
ASC REVIEW
Bill Walton,
NBA Legend and
Basketball Analyst
Kirk Herbstreit,
ESPN's "College
GameDay" Analyst
and Reporter
Alexa von Tobel,
Founder and CEO
of Learnvest.com,
Author of Financially
Fearless
Andrew Hayek,
CEO of OptumHealth,
CEO of Surgical Care
Affiliates
North American
Vertebroplasty Market to
Fall from $72M in 2016
to $29.4M by 2023 — 5
Observations
By Megan Wood
T
he North American vertebroplasty market will likely witness a 12 per-
cent negative compound annual growth rate through 2023, according to a
GlobalData analysis. Here are five observations:
1. e market is set to drop from $72 million in 2016 to $29.4 million by 2023.
2. Analysts noted procedure adoption is inconsistent because of sparse data
demonstrating vertebroplasty's efficacy.
3. e risk of cement leakage and damage to the surrounding spinal canal and
nerves deters wide adoption of the procedure.
4. In developing markets such as the Middle East and Africa, however, the market
will likely grow at a compound annual growth rate of 6.8 percent through 2023.
is growth is due to the cost-effectiveness of the procedure.
5. DePuy Synthes, Medtronic and Stryker account for about 80 percent of the
market share. n
